公开(公告)号：US20240158469A1

公开(公告)日：2024-05-16

申请号：US18421142

申请日：2024-01-24

申请人： ASTRAZENECA AB

发明人： GORDON MOODY ,  MARIA LETIZIA GIARDINO TORCHIA ,  MICHAEL GLEN OVERSTREET ,  RYAN GILBRETH

IPC分类号： C07K14/71 ,  A61K35/17 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32

CPC分类号： C07K14/71 ,  A61K35/17 ,  A61K38/177 ,  A61K38/1774 ,  A61K38/179 ,  A61K39/3955 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/464474 ,  A61K45/06 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70567 ,  C07K14/70578 ,  C07K14/7151 ,  C07K14/7153 ,  C07K16/2803 ,  C07K16/2827 ,  C07K16/283 ,  C07K16/2836 ,  C07K16/2866 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/303 ,  C07K16/3092 ,  C07K16/32 ,  A61K2239/21 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/32

摘要： This disclosure relates to compositions and methods for treating cancer using armored chimeric antigen receptor cells.

公开(公告)号：US20240150476A1

公开(公告)日：2024-05-09

申请号：US18393918

申请日：2023-12-22

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： Tomoyuki IGAWA ,  Hiroyuki ISHIKAWA ,  Naoka HIRONIWA

IPC分类号： C07K16/28 ,  C07K16/30 ,  C40B40/10 ,  G01N33/68

CPC分类号： C07K16/2866 ,  C07K16/2809 ,  C07K16/303 ,  C40B40/10 ,  G01N33/6854 ,  C07K2317/22 ,  C07K2317/31 ,  C07K2317/569 ,  C07K2319/50

摘要： The present invention relates to a polypeptide comprising an antigen binding domain and a carrying moiety having an inhibiting domain that inhibits the antigen binding activity of the antigen binding domain, and having a longer half-life than that of the antigen binding domain existing alone, methods for producing and screening for the polypeptide, a pharmaceutical composition comprising the polypeptide, methods for producing and screening for a single-domain antibody whose antigen binding activity is inhibited by associating with particular VL, VH or VHH, and a fusion polypeptide library including a single-domain antibody whose antigen binding activity is inhibited by associating with particular VL, VH or VHH.

公开(公告)号：US20240150460A1

公开(公告)日：2024-05-09

申请号：US18279014

申请日：2022-02-25

申请人： Shenghe (China) Biopharmaceutical Co., Ltd.

发明人： Jinhua ZHOU ,  Cailin ZHU ,  Chongbing WU ,  Xiaoling JIANG ,  Liusong YIN

IPC分类号： C07K16/28 ,  C07K14/475 ,  C07K14/495 ,  C07K14/535 ,  C07K14/54 ,  C07K14/555 ,  C07K16/30 ,  C07K16/32

CPC分类号： C07K16/2803 ,  C07K14/475 ,  C07K14/495 ,  C07K14/535 ,  C07K14/54 ,  C07K14/5421 ,  C07K14/5428 ,  C07K14/5443 ,  C07K14/555 ,  C07K16/28 ,  C07K16/2827 ,  C07K16/283 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/303 ,  C07K16/3069 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/569

摘要： The present invention discloses an anti-NKp30 single domain antibody capable of activating the release of cytokines from NK cells or γδT cells, and a nucleic acid encoding the anti-NKp30 single domain antibody. The present invention also discloses a multifunctional fusion protein comprising the anti-NKp30 single domain antibody and a composition thereof, and the use in drugs for the treatment, prevention or diagnosis of diseases.

公开(公告)号：US11932702B2

公开(公告)日：2024-03-19

申请号：US17553908

申请日：2021-12-17

申请人： Ablynx N.V. ,  Sanofi

发明人： Daniel Janssen ,  Carlo Boutton ,  Evelyne Dombrecht ,  Bram Laukens ,  Paolo Meoni ,  Lily Pao ,  Jan Pype ,  Peter Schotte ,  Benedikte Serruys ,  Ana Paula Vintem ,  Diane Van Hoorick

IPC分类号： C07K16/30 ,  A61P35/00 ,  C07K16/28 ,  A61K39/00

CPC分类号： C07K16/303 ,  A61P35/00 ,  C07K16/2809 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/30

摘要： The present technology aims at providing a novel type of drug for treating a subject suffering from cancer. Specifically, the technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that one ISVD binds to TCR and at least two ISVDs bind to GPC3. The present technology also provides nucleic acids, vectors and compositions.

公开(公告)号：US11913023B2

公开(公告)日：2024-02-27

申请号：US17465759

申请日：2021-09-02

申请人： Walking Fish Therapeutics

发明人： Kathleen Boyle ,  Hangil Park ,  Srinivas Kothakota ,  Mark Selby ,  Thomas Brennan ,  Lewis T. Williams

IPC分类号： C12N5/0781 ,  A61K35/17 ,  C07K16/30

CPC分类号： C12N5/0635 ,  A61K35/17 ,  C07K16/303 ,  C07K16/3069 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2319/03 ,  C12N2510/00

摘要： The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.

公开(公告)号：US20240058384A1

公开(公告)日：2024-02-22

申请号：US18501604

申请日：2023-11-03

申请人： SENTI BIOSCIENCES, INC.

发明人： Marcela Guzman Ayala

IPC分类号： A61K35/17 ,  C07K16/30 ,  A61P35/00 ,  A61K39/00

CPC分类号： A61K35/17 ,  C07K16/303 ,  A61P35/00 ,  A61K39/4611 ,  A61K39/4644 ,  A61K39/4613 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/53 ,  A61K2239/13

摘要： The present disclosure provides compositions and methods related to chimeric antigen receptors (CARs). In particular, the present disclosure provides CAR-based immunotherapeutic compositions that target tumor cells expressing glypican-3 (GPC3) for the treatment and prevention of cancer.

公开(公告)号：US20240026006A1

公开(公告)日：2024-01-25

申请号：US18366930

申请日：2023-08-08

申请人： Chugai Seiyaku Kabushiki Kaisha ,  Genentech, Inc.

发明人： Mika ENDO ,  Atsuhiko KATO ,  Toshihiko OHTOMO ,  Kenji ADACHI ,  Yasuko KINOSHITA ,  Yoshinori NARITA

IPC分类号： C07K16/28 ,  A61P35/00 ,  C07K16/30

CPC分类号： C07K16/2827 ,  A61P35/00 ,  C07K16/303 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/76

摘要： The invention provides compositions and methods for treating cancers. The methods comprising administering a PD-1 axis binding antagonist and an anti-GPC3 antibody. The compositions comprising a pharmaceutical composition for treating cancer which comprises a PD-1 axis binding antagonist and an anti-GPC3 antibody. Also disclosed are a pharmaceutical composition to be used in combination with a PD-1 axis binding antagonist for treating cancer which comprises an anti-GPC3 antibody as the active ingredient; and a pharmaceutical composition to be used in combination with an anti-GPC3 antibody for treating cancer which comprises as the active ingredient a PD-1 axis binding antagonist.

公开(公告)号：US20240024499A1

公开(公告)日：2024-01-25

申请号：US18252864

申请日：2021-11-19

申请人： ARDEAGEN CORPORATION

发明人： Maria Leia SMITH ,  May Kung SUTHERLAND

IPC分类号： A61K47/68 ,  C07K16/30 ,  A61K45/06 ,  A61P35/00

CPC分类号： A61K47/6809 ,  C07K16/303 ,  A61K47/6859 ,  A61K45/06 ,  A61P35/00

摘要： The present invention provides anti-GPC3 antibodies, antigen binding portions thereof and GPC3 conjugates thereof for use in the treatment of cancer.

公开(公告)号：US20240002793A1

公开(公告)日：2024-01-04

申请号：US18314778

申请日：2023-05-09

申请人： Walking Fish Therapeutics

发明人： Kathleen Boyle ,  Hangil Park ,  Srinivas Kothakota ,  Mark Selby ,  Thomas Brennan ,  Lewis T. Williams

IPC分类号： C12N5/0781 ,  A61K35/17 ,  C07K16/30

CPC分类号： C12N5/0635 ,  A61K35/17 ,  C07K16/303 ,  C07K16/3069 ,  C07K2317/53 ,  C07K2319/03 ,  C12N2510/00 ,  C07K2317/622

摘要： The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell”), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.

公开(公告)号：US11819553B2

公开(公告)日：2023-11-21

申请号：US16970095

申请日：2019-02-15

申请人： Seagen Inc.

发明人： Travis Biechele ,  William Arthur ,  Patrick Burke ,  Lori Westendorf

IPC分类号： A61P35/00 ,  A61K31/454 ,  A61K47/68 ,  C07K16/30 ,  A61K39/00

CPC分类号： A61K47/6859 ,  A61K31/454 ,  A61K47/6803 ,  A61P35/00 ,  C07K16/303 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/92

摘要： The invention provides murine, chimeric, and humanized antibodies that specifically bind to GPC3 and conjugates thereof.